Publications

• Law360: Medicare Advantage Plans Must Beware DOJ Scrutiny
  5 January 2022
  Law360
  Winston M. Paes
  ,
  Kristin D. Kiehn
  ,
  Adam Aukland-Peck
• The Eleventh Circuit Precludes “Administrative Feasibility” but Provides a Path Forward for Defendants Opposing Class Certification in Consumer Class Actions
  9 February 2021
  Maura Kathleen Monaghan
  ,
  Kristin D. Kiehn
  ,
  Jacob W. Stahl
  ,
  Adam Aukland-Peck
  ,
  Harold W. Williford
  ,
  Kelly Rose O'Reilly
• Consolidated Appropriations Act: Implications for Healthcare and Life Sciences Companies
  30 December 2020
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Kristin D. Kiehn
  ,
  Jacob W. Stahl
  ,
  Kim T. Le
  ,
  Melissa Runsten
• Federal Government Shines Spotlight on Speaker Programs
  20 November 2020
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Paul D. Rubin
  ,
  Kristin D. Kiehn
  ,
  Jacob W. Stahl
  ,
  Kim T. Le
  ,
  Melissa Runsten
• Ninth Circuit Decision Increases Risk of RICO Economic Loss Claims Against Pharmaceutical Manufacturers and Highlights Evolving Circuit Split
  6 March 2020
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kristin D. Kiehn
  ,
  J. Robert Abraham
• A Walk in the Park Shouldn’t Lead to Jail Time: Recent Decisions Explain Why Incarceration Is Never Appropriate for ‘Responsible Corporate Officers’ Who Lack Criminal Intent
  7 October 2016
  Bloomberg BNA Pharmaceutical Law & Industry Report
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Helen V. Cantwell
  ,
  Kristin D. Kiehn
  ,
  Jacob W. Stahl
• It’s A Hard-Knock Life: The Rough-And-Tumble Fight Over Orphan Drug Pricing
  12 January 2016
  American Bar Association
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kristin D. Kiehn
  ,
  Jacob W. Stahl
• Speedy Returns: The 60-Day Rule
  January 12 2016
  American Bar Association
  Maura Kathleen Monaghan
  ,
  Kristin D. Kiehn
  ,
  Jacob W. Stahl
• First Circuit Holds That Federal Law Preempts State-Law Claims Involving a Branded Drug Label
  4 March 2015
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kristin D. Kiehn
  ,
  J. Robert Abraham
• Ninth Circuit Affirms District Court Order to Unwind Hospital Merger
  13 February 2015
  Gary W. Kubek
  ,
  Mark P. Goodman
  ,
  Andrew L. Bab
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Kristin D. Kiehn
  ,
  Erica S. Weisgerber
• It’s A Hard-Knock Life: The Rough-And-Tumble Fight Over Orphan Drug Pricing
  14 November 2014
  Bloomberg BNA’s Pharmaceutical Law & Industry Report
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kristin D. Kiehn
  ,
  Jacob W. Stahl
• DOJ Proposal Shows Focus on Individuals in Corporate Crime
  30 September 2014
  Law360
  Helen V. Cantwell
  ,
  Matthew E. Fishbein
  ,
  Mark P. Goodman
  ,
  Mary Beth Hogan
  ,
  Andrew M. Levine
  ,
  Jonathan R. Tuttle
  ,
  Bruce E. Yannett
  ,
  Kristin D. Kiehn
  ,
  David Sarratt
  ,
  Jacob W. Stahl
• Provocative DOJ Proposal Aims to Hold Financial Services Executives Criminally Liable, Even Absent Criminal Intent
  22 September 2014
  Bruce E. Yannett
  ,
  Mary Beth Hogan
  ,
  Helen V. Cantwell
  ,
  Matthew E. Fishbein
  ,
  Mark P. Goodman
  ,
  Andrew M. Levine
  ,
  Jonathan R. Tuttle
  ,
  Kristin D. Kiehn
  ,
  Jacob W. Stahl
• Compliance Corner: The Clock Is Ticking: 60-Day Rule and FCA Liability for Overpayments
  17 September 2014
  Bloomberg BNA’s Health Care Fraud Report
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kristin D. Kiehn
  ,
  Jacob W. Stahl
• FDA Issues Proposed Guidance on Social Media and Internet Communications for Pharmaceutical and Medical Device Manufacturers
  27 June 2014
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kristin D. Kiehn
  ,
  Jacob W. Stahl
• Vicarious Criminal Liability in the Executive Suite for Problems on the Manufacturing Floor
  4 April 2014
  Bloomberg BNA’s Pharmaceutical Law & Industry Report
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kristin D. Kiehn
  ,
  Jacob W. Stahl
• Supreme Court Expands “Impossibility” Preemption to Design Defect Claims against Generic Drug Manufacturers
  26 June 2013
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kristin D. Kiehn
  ,
  J. Robert Abraham
• FCPA Update
  April 2013, Vol. 4, No.9
  Paul R. Berger
  ,
  Bruce E. Yannett
  ,
  Andrew M. Levine
  ,
  Erich O. Grosz
  ,
  Samantha J. Rowe
  ,
  Kristin D. Kiehn
  ,
  Dmitri V. Nikiforov
  ,
  Jane Shvets
• Second Circuit Concludes Truthful Off-Label Promotion Is Not Unlawful: Free Speech, But Not A Free Pass (Yet)
  5 December 2012
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Andrew M. Levine
  ,
  Kristin D. Kiehn
• GSK's $3 Billion Settlement Reflects Continued Expansion In Scope Of Pharma Plea Agreements
  August 2012
  Rx Compliance Report
  Kristin D. Kiehn
  ,
  Maura Kathleen Monaghan
  ,
  Mark P. Goodman
• GSK $3 Billion Settlement Reflects Continued Expansion in Scope of Pharma Plea Agreements
  9 July 2012
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kristin D. Kiehn
• An Unprecedented Settlement For FDCA Violation
  22 May 2012
  Law360
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kristin D. Kiehn
• Abbott Settlement Includes Unprecedented Term of Probation, Mandatory Compliance Measures
  10 May 2012
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kristin D. Kiehn
• Supreme Court Rules in Two Pharma Cases
  29 June 2011
  Anne E. Cohen
  ,
  Andrew L. Bab
  ,
  Kevin Rinker
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kristin D. Kiehn
• Bruesewitz v. Wyeth: Express Preemption Returns to the Fore
  23 February 2011
  Maura Kathleen Monaghan
  ,
  Roger E. Podesta
  ,
  Mark P. Goodman
  ,
  Anne E. Cohen
  ,
  Mary Beth Hogan
  ,
  Kristin D. Kiehn